Regulatory
Medicare's Evolution from Passive Payer to Value-Driven Purchaser of Healthcare
The Clinical and Economic Complexity of Biologics
Policy Considerations in Evidence-Based Coverage Decisions
Part D under the Medicare Improvements for Patients and Providers Act of 2008
The Many Challenges of Pay-for-Performance Programs
Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point?
Orphan Drugs: The Potential Impact of Generic Biologics
The Missing Quality Standard for Medication Adherence
Potential Benefits of Prediction Models from Large Electronic Databases